Immunology and Immunochemistry are two interconnected fields of study that play vital roles in understanding the immune system and the development of vaccines. Immunology focuses on the study of the immune system, including its structure, function, and response to pathogens, while immunochemistry delves into the chemical processes underlying immune reactions and interactions between antigens and antibodies. Vaccines harness the principles of immunology and immunochemistry to stimulate the body's immune response and provide protection against infectious diseases. They contain antigens derived from pathogens, such as viruses or bacteria, which trigger the immune system to recognize and mount a defensive response.
When a vaccine is administered, the antigens it contains are recognized by specialized cells of the immune system, such as dendritic cells and macrophages. These cells process the antigens and present them to other immune cells, known as T cells and B cells, which play key roles in coordinating the immune response. T cells, also known as T lymphocytes, help to orchestrate the immune response by recognizing and destroying infected cells and releasing signaling molecules called cytokines that regulate the activity of other immune cells. B cells, on the other hand, produce antibodies, proteins that specifically bind to and neutralize the antigens.
The interaction between antigens and antibodies is central to the immune response and is governed by the principles of immunochemistry. Antibodies, also known as immunoglobulins, are Y-shaped proteins produced by B cells that bind to specific antigens with high affinity. Vaccines can contain whole pathogens, live attenuated or inactivated pathogens, specific protein subunits or antigens derived from pathogens, or genetic material encoding viral antigens. Each type of vaccine elicits a different immune response and provides varying degrees of protection against the targeted disease.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe